Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...
A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...
Even as AbbVie has demonstrated that Rinvoq and Skyrizi sales can more than make up for Humira's tumble over the patent cliff ...
For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...
As the commercial momentum behind Lilly’s tirzepatide franchise continues, analysts are increasingly turning their attention ...
Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial ...
Roughly one year into launch, Lenz Therapeutics, the maker of Vizz eye drops fo | In a massive overhaul of its operating ...
Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...
Several months after telegraphing a major antibody-drug conjugate manufacturing expansion in its native Switzerland, CDMO ...
Amgen has been handed an FDA warning letter over a video promoting its cancer drug Vectibix, but the company said the issues ...
Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...
Amid a push to win back investor confidence in its R&D trajectory, Sanofi still has significant commercial powder to burn with Dupixent, as illustrated in a third-quarter showing that looked strong by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results